© 2019 The Author(s) Published by Cell Physiol Biochem Press GmbH&Co. KG, Duesseldorf www.cellphysiolbiochem.com

281

Erratum

In the original article by Xiao, et al., entitled "Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells" [Cell Physiol Biochem 2018;51(4):1879-1893, DOI: 10.1159/000495714], there is a mistake in Fig. 3C. The correct Fig. 3 is displayed below.

The authors confirm that all of the results and conclusions of the article remain unchanged, as well as the figure legend.

The authors sincerely apologize for this mistake.




Fig. 3. Transfection of CD44 sgRNA-Cas9-GFP significantly inhibits CD44 expression. A. Fluorescence analysis show that most of KHOSR2 and U-2OSR2 cells transfected with CD44-Cas9-GFP or pEGFP-N3 plasmids contain green fluorescence, which suggests that KHOSR2 and U-2OSR2 cells were successfully, introduced CD44-Cas9-GFP or pEGFP plasmids. This assay was repeated three times. B. Western blots showing CD44-Cas9-GFP system could effectively knock out CD44. The western bolt was performed in triplicate. C. Immunofluorescence photos for CD44 (red) and nuclei (blue) of KHOSR2 and U-2OSR2 cells transfected with CD44-Cas9-GFP plasmids. This assay was repeated twice.